Fractyl Health, Inc. (GUTS)

NGM – Real Time Price. Currency in USD

0.45

-0.02 (-5.20%)

At close: Mar 27, 2026, 4:00 PM EDT

0.46

+0.01 (2.54%)

After-hours: Mar 27, 2026, 7:52 PM EDT

About the company

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Key Executives

Name	Position
Dr. Harith Rajagopalan M.D., Ph.D.	Co-Founder, CEO & Director
Mr. Brian Luque	Head of Investor Relations & Corporate Development
Mr. Jay D. Caplan BSEE, MBA	Co-Founder, Chief Product Officer & President
Mr. Jon Fitzgerald	Senior Vice President of Regulatory, Quality & Clinical
Ms. Lara Smith Weber	Chief Financial Officer
Ms. Sarah S. Toomey Esq.	General Counsel & Corporate Secretary